English
|
Spanish
Supporting oncology professionals through education
Login
Register
The content on this site is intended for healthcare professionals only
Menu
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
News
Latest news
Sign up for news alerts
Submit your news
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Journal information
Journal home
Charges
Editorial board
Founding editors
Editor-in-chief
Contact us
Author information
Submit article
Author guidelines
Editorial policies
Copyright information
Why publish with us
Reviewer information
Reviewer guidelines
Memberships
Videos
Recent videos
Sign up
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Conferences
Latest conferences
Sign up for latest coverage
Submit your event
About
e
cancer
About
e
cancer
Our founders
Funding statement
Contact us
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
Costs of licensing clinical trials
Share :
ECCO 15 - ESMO 34
20 - 24 Sep 2009
Please rate this video
The information in this video was of interest to me
The information in this video is likely to improve my clinical practice or research
I would recommend this video to my colleagues
Published:
3 Nov 2009
Views:
10277
Rating:
Save
Rate video
Prof. John Smyth - Assistant Principal Cancer Research Development, University of Edinburgh
Discusses the issue of the cost of licensing trials with managing editor Professor Gordon McVie, at ECCO 15 - ESMO 34, Berlin, 2009.
Categories:
Drug development
Related Videos
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance...
Dr Jill Corre - IUCT Oncopole, Toulouse, France
29 Oct 2024
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...
Prof Xavier Leleu - CHU de Poitiers, Poitiers, France
28 Oct 2024
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Dr Elias Mai - Heidelberg University, Heidelberg, Germany
28 Oct 2024
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Prof Joy Ho - The University of Sydney, Sydney, Australia
28 Oct 2024
Guiding transplant decisions in multiple myeloma with MRD
Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA
28 Oct 2024
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale...
18 Oct 2024
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced...
Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA
16 Oct 2024
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Dr Prashant Mehta - Amrita Hospital, Karala, India
10 Oct 2024
Optimizing oncology: The future of treatment studies
Dr Daniel A. Goldstein - University of North Carolina, USA
10 Oct 2024
More from
e
cancer